AlphaSituations-Event/Catalyst Driven Research, AlphaSituations

Robert Sassoon

Robert Sassoon has been an equity analyst for more than twenty years focusing primarily on global special situations. Robert has worked in research for several large sell-side institutions, including Credit Suisse, Natwest Capital Markets and Societe Generale. During his career, he has achieved top 5 rankings in various analyst surveys, including the Extel and Greenwich surveys.

In 2017, Robert founded AlphaSituations, an idea-generating investment research service with the goal of delivering a unique portfolio of ideas to drive client growth and returns by uncovering compelling and highly profitable value propositions as well as lucrative shorter-term trading situations arising from select dislocating corporate restructuring events and catalysts. Currently, the main geographical focus of the research is North America. Since its establishment, AlphaSituations has delivered a track record of outperformance with a hit rate of winners of more than 70% of its portfolio of ideas generating annualized average returns of 20%.

In January 2022, AlphaSituations was contracted  by Water Tower Research,  an investor engagement and stakeholder communication platform to provide coverage of Special Situations.

AlphaSituations-Event/Catalyst Driven Research

MergerTalk: Healthcare Merger/SOC Telemed-Why This Deal Can Join The Exclusive SPAC Winners Club

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

AlphaSituations

Since its establishment, AlphaSituations has delivered a track record of outperformance with a hit rate of winners of more than 70% of its portfolio of ideas generating annualized average returns of 20%. In January 2022, AlphaSituations was contracted by Water Tower Research, an investor engagement and stakeholder communication platform to provide coverage of Special Situations

Event-Driven

On September 11, 2020, we published an Insight on the then pending merger of SPAC Healthcare Merger Corp with with SOC Telemed, a leader in high acute telemedicine (MergerTalk: Healthcare Merger/SOC Telemed-Why This Deal Can Join The Exclusive SPAC Winners Club). In that insight, we laid out the case for why we think SOC Telemed's backdoor listing via this SPAC merger, is well positioned to be a winning investment. 
The merger was completed on October 30, 2020,  and the post merger entity, <a href="https://www.smartkarma.com/entities/soc-telemed-inc" target="_blank" data-smartkarma-citation="entities:29273:1" rel="noopener">SOC Telemed (TLMD US)</a>, began trading on the NASDAQ from November 2, 2020, but, the listing has so far been underwhelming with the stock trading below Healthcare Merger's IPO price of $10. Following close on the heels of the American Well Corp (AMWL US) IPO and the completion of the <a href="https://www.smartkarma.com/entities/teladoc-health-inc" target="_blank" data-smartkarma-citation="entities:14233:1" rel="noopener">Teladoc Health, Inc. (TDOC US)</a> /Livongo meger, we believe that TLMD's enticing story has simply got lost in the crowd. Consequently, we believe TLMD trades at an undeservedly wide valuation gap to peers in the Teleleheralth sector.
On November 16, 2020, TLMD was presented with its first opportunity post-merger to retell its story when it reported its 3Q 2020 earnings, and did not disappoint. We also believe this is a story worth retelling. We hold a high conviction that this stock will considerably narrow its valuation gap relative to its peers during the course of 2021 as investors become more familiar with a newer type of business model in Teleheath.

On September 11, 2020, we published an Insight on the then pending merger of SPAC Healthcare Merger Corp with with SOC Telemed, a leader in high acute telemedicine (MergerTalk: Healthcare Merger/SOC Telemed-Why This Deal Can Join The Exclusive SPAC Winners Club). In that insight, we laid out the case for why we think SOC Telemed's backdoor listing via this SPAC merger, is well positioned to be a winning investment. 
The merger was completed on October 30, 2020,  and the post merger entity, SOC Telemed (TLMD US), began trading on the NASDAQ from November 2, 2020, but, the listing has so far been underwhelming with the stock trading below Healthcare Merger's IPO price of $10. Following close on the heels of the American Well Corp (AMWL US) IPO and the completion of the Teladoc Health, Inc. (TDOC US) /Livongo meger, we believe that TLMD's enticing story has simply got lost in the crowd. Consequently, we believe TLMD trades at an undeservedly wide valuation gap to peers in the Teleleheralth sector.
On November 16, 2020, TLMD was presented with its first opportunity post-merger to retell its story when it reported its 3Q 2020 earnings, and did not disappoint. We also believe this is a story worth retelling. We hold a high conviction that this stock will considerably narrow its valuation gap relative to its peers during the course of 2021 as investors become more familiar with a newer type of business model in Teleheath. 

2021 High Conviction - MergerTalk:SOC Telemed- Acutely Underappreciated Investment Proposition